$511 Million is the total value of Opaleye Management Inc.'s 55 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AFIB | New | ACUTUS MEDICAL INC | $22,350,000 | – | 749,990 | +100.0% | 4.37% | – |
| PCVX | New | VAXCYTE | $15,456,000 | – | 313,000 | +100.0% | 3.02% | – |
| TCON | New | TRACON PHARMACEUTICALS INC | $10,409,000 | – | 2,013,438 | +100.0% | 2.04% | – |
| MCRB | New | SERES THERAPEUTICS | $9,493,000 | – | 335,312 | +100.0% | 1.86% | – |
| AXGT | New | AXOVANT SCIENCES LTD | $9,421,000 | – | 2,039,100 | +100.0% | 1.84% | – |
| FULC | New | FULCRUM THERAPEUTICS INC | $3,584,000 | – | 452,000 | +100.0% | 0.70% | – |
| LUMO | New | LUMOS PHARMA INC | $3,329,000 | – | 240,892 | +100.0% | 0.65% | – |
| KZR | New | KEZAR LIFE SCIENCES INC | $3,282,000 | – | 678,000 | +100.0% | 0.64% | – |
| VSTM | New | VERASTEM INC | $3,201,000 | – | 2,200,000 | +100.0% | 0.63% | – |
| AGLE | New | AEGLEA BIOTHERAPEUTICS INC | $2,659,000 | – | 375,000 | +100.0% | 0.52% | – |
| NERV | New | MINERVA NEUROSCIENCES INC | $2,440,000 | – | 767,400 | +100.0% | 0.48% | – |
| OM | New | OUTSET MED INC | $2,250,000 | – | 45,000 | +100.0% | 0.44% | – |
| STRO | New | SUTRO BIOPHARMA INC | $1,467,000 | – | 146,000 | +100.0% | 0.29% | – |
| CFRX | New | CONTRAFECT INC | $1,194,000 | – | 226,127 | +100.0% | 0.23% | – |
| CNCE | New | CONCERT PHARMACEUTICALS INC | $982,000 | – | 100,000 | +100.0% | 0.19% | – |
| XFOR | New | X4 PHARMACEUTICALS INC | $508,000 | – | 75,000 | +100.0% | 0.10% | – |
| ONCT | New | ONCTERNAL THERAPEUTICS INC | $331,000 | – | 194,541 | +100.0% | 0.06% | – |
| PIRS | New | PIERIS PHARMACEUTICALS INC | $300,000 | – | 145,000 | +100.0% | 0.06% | – |
| INFI | New | INFINITY PHARMACEUTICALS INC | $137,000 | – | 3,171,800 | +100.0% | 0.03% | – |
| MRUS | New | MERUS NV | $2,000 | – | 200 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.